- Home
- FGEN vs ANEB Comparison
FGEN vs ANEB Comparison
Compare FGEN & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- ANEB
- Stock Information
- Founded
- FGEN 1993
- ANEB 2020
- Country
- FGEN United States
- ANEB United States
- Employees
- FGEN N/A
- ANEB N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- ANEB Health Care
- Exchange
- FGEN Nasdaq
- ANEB Nasdaq
- Market Cap
- FGEN 45.0M
- ANEB 98.6M
- IPO Year
- FGEN 2014
- ANEB 2021
- Fundamental
- Price
- FGEN $10.92
- ANEB $2.32
- Analyst Decision
- FGEN Strong Buy
- ANEB Buy
- Analyst Count
- FGEN 2
- ANEB 2
- Target Price
- FGEN $146.50
- ANEB $8.00
- AVG Volume (30 Days)
- FGEN 29.9K
- ANEB 50.8K
- Earning Date
- FGEN 11-11-2025
- ANEB 11-12-2025
- Dividend Yield
- FGEN N/A
- ANEB N/A
- EPS Growth
- FGEN N/A
- ANEB N/A
- EPS
- FGEN N/A
- ANEB N/A
- Revenue
- FGEN $7,346,000.00
- ANEB N/A
- Revenue This Year
- FGEN N/A
- ANEB N/A
- Revenue Next Year
- FGEN N/A
- ANEB N/A
- P/E Ratio
- FGEN N/A
- ANEB N/A
- Revenue Growth
- FGEN N/A
- ANEB N/A
- 52 Week Low
- FGEN $4.50
- ANEB $0.80
- 52 Week High
- FGEN $21.94
- ANEB $3.42
- Technical
- Relative Strength Index (RSI)
- FGEN 44.16
- ANEB 45.32
- Support Level
- FGEN $10.29
- ANEB $2.26
- Resistance Level
- FGEN $12.13
- ANEB $2.39
- Average True Range (ATR)
- FGEN 0.58
- ANEB 0.10
- MACD
- FGEN -0.25
- ANEB -0.01
- Stochastic Oscillator
- FGEN 23.58
- ANEB 26.45
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies.